Finasteride
Product Images NDC 68071-2695

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68071-2695). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2695 3)

Label for Finasteride 5 mg tablets by NuCare Pharmaceuticals, Inc. The label states the product contains 30 tablets and includes the NDC number 68071-2695-3. It advises to see the manufacturer's label for the full list of ingredients and includes warnings to keep out of reach of children and store at controlled temperature 68-77°F. The label also provides manufacturer and distributor information, lot and expiration placeholders, and a note about reporting side effects to the FDA.*

FDA Label Image

Address.jpg (Address)

FDA Label Image

Address3.jpg (Address3)

FDA Label Image

Figure1.jpg (Figure1)

A line graph comparing mean changes from baseline over four years between Finasteride and placebo groups. The vertical axis represents the mean change, while the horizontal axis shows time points from baseline to year 4. The Finasteride group shows a steady decrease, while the placebo group remains near baseline.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph titled 'Figure 2 Percent of Patients Having Surgery for BPH, Including TURP' comparing Finasteride and placebo groups. The x-axis represents observation time in months (0 to 48), and the y-axis shows the percent of patients (0% to 15%). Two lines are plotted: one for Finasteride and one for placebo, with placebo showing a higher percentage over time. Below the graph, cumulative event counts and patients at risk per year are tabulated for each group.*

FDA Label Image

Figure3.jpg (Figure3)

Line graph showing mean percent change from baseline with standard error over four years for two groups: Placebo and Finasteride. The placebo group shows an increasing positive trend, while the Finasteride group shows a decreasing trend, beginning below baseline and remaining relatively stable after Year 2. Sample sizes for each group at different time points are listed below the graph.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph depicting the percent of participants experiencing an event over approximately 5.5 years from randomization. Four labeled series show outcomes for Placebo, Finasteride, Doxazosin, and Combination treatments, with percent event rates increasing over time and Placebo showing the highest event percent.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure of finasteride, showing its steroidal backbone with attached functional groups including a ketone and a tertiary amide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.